Skip to main content
. 2018 Dec 30;2018:2952085. doi: 10.1155/2018/2952085

Table 4.

Mechanism of anticancer activity of nanochitosan (composite) in some target cells.

Nanochitosan (composite) Target cell(s) Mechanism of action Test Outcome Year Ref.
Nano chitosan Breast cancer mice model 4 Interference to RNA and immunoenhancement In vivo Inhibition of angiogenesis and proliferation 2010 
2015
[17] 
[211]
Human gastric cancer cells Sustained release manner In vitro Inhibition of cells proliferation 2010 
2005
[17] 
[213]
Ovarian cancer cells Binding of αvβ3 integrin with tumor cell receptors In vivo Inhibition of tumor growth 2010 [216]
HCC cells Decrease in mitochondrial membrane potential, and fragmentation of DNA, suppression of VEGFR2 gene expression In vitro Cell death and inhibition of angiogenesis 2010 
2007
[17] 
[95]

Paclitaxel-glycol chitosan nano composite MCF-7 sustained release of paclitaxel by EPR effect In vitro Tumor growth inhibition 2006 [214]

Chitosan-curcumin nano formulation Solid tumor Sustained release manner, DNA damage, cell cycle blockage and elevation of ROS levels In vitro Inhibition of tumor growth 2018 [219]

Chitosan folate hesperetin nanoparticles HCT15 cells Passive targeting through the leaky vasculature of tumor environment In vivo Cellular apoptosis 2018 [220]

Peptide-labeled chitosan nanoparticle Solid tumors Tumor targeted delivery for short interfering RNA (siRNA) In vivo Inhibition of tumor growth 2010 [216]